FY2024 EPS Estimates for ZVRA Decreased by Cantor Fitzgerald

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Cantor Fitzgerald lowered their FY2024 earnings estimates for shares of Zevra Therapeutics in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($1.97) for the year, down from their previous forecast of ($1.61). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

A number of other equities analysts also recently weighed in on ZVRA. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Guggenheim started coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. Roth Mkm upped their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Monday, September 30th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $8.62 on Monday. The firm’s 50 day simple moving average is $8.03 and its 200-day simple moving average is $6.50. The company has a market cap of $453.58 million, a P/E ratio of -4.38 and a beta of 1.93. Zevra Therapeutics has a fifty-two week low of $4.18 and a fifty-two week high of $9.21. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the firm posted ($0.40) EPS.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Zevra Therapeutics in the 1st quarter valued at approximately $64,000. Jacobs Levy Equity Management Inc. boosted its position in Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after acquiring an additional 17,557 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Zevra Therapeutics by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after acquiring an additional 21,231 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Zevra Therapeutics by 17.9% in the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock valued at $279,000 after purchasing an additional 8,619 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.